Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography
- PMID: 1999624
- DOI: 10.1016/0735-1097(91)90869-b
Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography
Abstract
To assess regional coronary reserve in hypertrophic cardiomyopathy, regional myocardial blood flow was measured in 23 patients with hypertrophic cardiomyopathy and 12 control subjects by means of nitrogen-13 ammonia and dynamic positron emission tomography. In patients with hypertrophic cardiomyopathy at baseline study, regional myocardial blood flow was 1.14 +/- 0.43 ml/min per g in the hypertrophied (20 +/- 3 mm) interventricular septum and 0.90 +/- 0.35 ml/min per g (p less than 0.05 versus septal flow) in the nonhypertrophied (10 +/- 2 mm) left ventricular free wall. These were not statistically different from the corresponding values in control subjects (1.04 +/- 0.25 and 0.91 +/- 0.21 ml/min per g, respectively, p = NS). After pharmacologically induced coronary vasodilation (dipyridamole, 0.56 mg/kg intravenously over 4 min), regional myocardial blood flow in patients with hypertrophic cardiomyopathy increased significantly less than in control subjects both in the septum (1.63 +/- 0.58 versus 2.99 +/- 1.06 ml/min per g, p less than 0.001) and in the free wall (1.47 +/- 0.58 versus 2.44 +/- 0.82 ml/min per g, p less than 0.001). In addition, patients with hypertrophic cardiomyopathy who had a history of chest pain had more pronounced impairment of coronary vasodilator reserve than did those without a history of chest pain. After dipyridamole, coronary resistance in the septum decreased by 38% in patients without a history of chest pain, but decreased by only 14% in those with such a history (p less than 0.05). Coronary resistance in the free wall decreased by 45% in patients without and by 27% in those with a history of chest pain (p = 0.06).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography.Eur Heart J. 1997 Jan;18(1):108-16. doi: 10.1093/oxfordjournals.eurheartj.a015090. Eur Heart J. 1997. PMID: 9049522
-
Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy.Am J Cardiol. 1994 Aug 15;74(4):363-8. doi: 10.1016/0002-9149(94)90404-9. Am J Cardiol. 1994. PMID: 8059699 Clinical Trial.
-
Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function.Eur Heart J. 1997 Dec;18(12):1946-50. doi: 10.1093/oxfordjournals.eurheartj.a015204. Eur Heart J. 1997. PMID: 9447323
-
Nitrogen-13 ammonia perfusion imaging: relation to metabolic imaging.Am Heart J. 1993 Mar;125(3):848-54. doi: 10.1016/0002-8703(93)90180-h. Am Heart J. 1993. PMID: 8438714 Review.
-
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy.J Cardiovasc Transl Res. 2009 Dec;2(4):452-61. doi: 10.1007/s12265-009-9142-5. Epub 2009 Nov 3. J Cardiovasc Transl Res. 2009. PMID: 20560003 Review.
Cited by
-
Why LV dilatation with vasodilator stress in hypertrophic cardiomyopathy?J Nucl Cardiol. 2016 Dec;23(6):1315-1318. doi: 10.1007/s12350-015-0180-x. Epub 2015 May 28. J Nucl Cardiol. 2016. PMID: 26017714 No abstract available.
-
The spectrum and systemic associations of microvascular dysfunction in the heart and other organs.Nat Cardiovasc Res. 2022 Apr;1(4):298-311. doi: 10.1038/s44161-022-00045-5. Epub 2022 Apr 13. Nat Cardiovasc Res. 2022. PMID: 39196132 Review.
-
Myocardial perfusion and coronary microcirculation: from pathophysiology to clinical application.J Nucl Cardiol. 2002 May-Jun;9(3):328-37. doi: 10.1067/mnc.2002.123914. J Nucl Cardiol. 2002. PMID: 12032481 Review. No abstract available.
-
Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):779-88. doi: 10.1007/s00259-009-1350-3. Epub 2010 Jan 13. Eur J Nucl Med Mol Imaging. 2010. PMID: 20069294
-
Coronary microvascular dysfunction: A review of recent progress and clinical implications.Front Cardiovasc Med. 2023 Jan 26;10:1111721. doi: 10.3389/fcvm.2023.1111721. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36776251 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous